$heff's $tation of $tocks & $olid DD

[spartakis1]

Got crushed on SVA today, still holding to try and get my money back at least. Do your own DD, this is reasons why I am holding.
Already dropped past my stop and don't like being down this much so hoping to recover.

If this ends up being true I believe Sinovac will be the ones getting the a deal.
http://www.theatlanticwire.com/global/2013/04/china-bird-flu-human-to-human/64339/

http://www.bloomberg.com/news/2013-04-15/bird-flu-surge-in-china-spurs-h7n9-pandemic-vaccine-preparations.html?cmpid=yhoo

What bears think
http://www.fool.com/investing/general/2013/04/18/why-sinovac-is-poised-to-keep-pulling-back.aspx

(In addition, yesterday, Dr. Zhu Fengcai, Deputy Director of the Jiangsu Provincial Center for Disease Control and who is the co-principal investigator of our Phase III trial, presented additional efficacy and safety data from the trial that was conducted in Jiangsu Province. On the 13th Annual World Vaccine Congress and Expo held in Washington DC, of the United States. And this data shows that EV71 vaccine has 95% efficacy, when compared to the placebo group, and safety was comparable, between the vaccine group and placebo group, and injection site and general adverse reaction was similar across both groups. We are working with the PR team to drop an article about this vaccine for a (inaudible) journal and we will make an announcement on the publish of this article, once it's completed.

Our clinical research and regulatory team are right now working on the summary reports of the clinical studies and also to prepare the new drug application dossier, and we expect to submit the application for the new drug license to China's FDA by the end of May.

Bird Flu H7 and H9
Our next question comes from the line of Yi Chen with Aegis Capital. Please proceed with your question.

Yi Chen - Aegis Capital
Hi. Thank you for taking my questions. My first question is, what is Chinese government's current opinion on whether it is necessary to develop that same for H7 and H9?

Weidong Yin - Chief Executive Officer
[Foreign Language].

Helen Yang - Investor Relations Manager
To translate Mr. Yin's answer to that question, actually Sinovac was engaged in developing vaccines against the potential pandemic of flu kind of viruses, starting from 2004, at the time, we were developing H5N1 vaccine. But after that many years, we actually -- we didn't obtain too much profit or revenues from these products, but we think we actually gathered the platforms, and people were trained to do that. By the year of 2009 and 2010, H1N1 caused a very serious pandemic, and Sinovac also led a research to develop a vaccine, and that actually gave the company a good opportunity, in terms of selling the vaccine and also to provide a vaccine stockpile by the government, and now, there is new viruses, also within the flu family, the H7 and H9 epidemic, that actually provides the possibility for Sinovac to do the research on another kinds of avian flu vaccines for humans.

.

Weidong Yin - Chief Executive Officer
[Foreign Language].

Helen Yang - Investor Relations Manager
As you remember that, actually in last year, we have completed our GMP certification for our new -- brand new filling and packaging line on our new site, and also our flu (inaudible) certification, GMP certification was completed as well, and we believe that Sinovac has the capability technically to develop a new type of avian flu vaccine for humans. However, there are big uncertainties of the epidemic situation, and whether this virus will come up through human-to-human transmission, and maybe some of you have seen that the company has explained to the media that once we obtain overseas from either the (inaudible), we will immediately start to do the development of the vaccine, and this partly is that we want to be a responsible company for the social society and also we think that even though there are some uncertainties, but we would like to be ready, once there is any good opportunities for us, and we would expect that our shareholders and our friends could be closely monitoring the situation with us, on how this epidemic would be developed in the next few months.


The reason their earnings was less
(2011 sales included recognition of approximately $14 million revenue from Panflu and Panflu.1 vaccines, stockpiled by the Chinese government in 2010. These two products are not for regular sales, since they were produced upon government order and subject to the government decision of using the vaccines within its shelf life, if there was any flu pandemic caused by H1N1 and/or H5N1. The company's revenue recognition requirements were not met until the fourth quarter of 2011; and in 2012, there was no revenue recognized for either Panflu or Panflu.1.

Compared with the fourth quarter of 2011, the gross profit margin for the fourth quarter of 2012 decreased from 62% to 54.1%. The high gross margin in the fourth quarter of 2011 was due to the recognition of $14 million in revenue from H1N1 vaccine stockpiling, which has higher gross margin than the other vaccines.)
http://seekingalpha.com/article/1351461-sinovac-biotech-s-ceo-discusses-f4q2012-results-earnings-call-transcript?page=5&p=qanda&l=last